In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.

The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Survival outcomes for patients with high-grade serous ovarian carcinoma may be ...

December 23, 2008 — In the treatment of advanced ovarian cancer, neoadjuvant chemotherapy before surgical debulking may be the new standard of care — especially in countries where the scheduling of a ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An easy-to-use, risk-based algorithm proved useful for ...

Effect of nilotinib on cell proliferation and migration of ovarian cancer cells alone and in combination with standard chemotherapy. Background: Advances in laparoscopic surgery have allowed a ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A minimally ...

Patients with advanced ovarian cancer who achieved complete cytoreduction had the best outcomes, regardless of the number of chemotherapy cycles before surgery. Increasing the number of chemotherapy ...

Significant disparities exist in the adoption of minimally invasive interval debulking surgery for advanced ovarian cancer, with gaps potentially widening as the procedure becomes more common.

Protein network mapping of platinum-resistant and poor-survival ovarian cancer. Continuous low-flow ascites drainage and sequential non-invasive tumor-cell sampling through the urinary bladder via the ...

Ovarian cancer patient Carol Giandonato admits to being apprehensive when her oncologist told her he wanted to make her cancer cells turn fluorescent green. “Am I going to glow in the dark? Will I be ...